122 related articles for article (PubMed ID: 38901650)
1. Pen2/ErbB4 signaling regulates stemness of pancreatic ductal carcinoma.
Zhu Z; Ding D; Hu H; He T
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(7):167316. PubMed ID: 38901650
[TBL] [Abstract][Full Text] [Related]
2. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
3. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.
Skoda J; Hermanova M; Loja T; Nemec P; Neradil J; Karasek P; Veselska R
PLoS One; 2016; 11(7):e0159255. PubMed ID: 27414409
[TBL] [Abstract][Full Text] [Related]
4. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma.
Song W; Li Q; Wang L; Huang W; Wang L
Sci Rep; 2015 Jun; 5():10081. PubMed ID: 26068418
[TBL] [Abstract][Full Text] [Related]
5. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.
Varillas JI; Zhang J; Chen K; Barnes II; Liu C; George TJ; Fan ZH
Theranostics; 2019; 9(5):1417-1425. PubMed ID: 30867841
[No Abstract] [Full Text] [Related]
6. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
Jia X; Chen L; Yu C
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
[TBL] [Abstract][Full Text] [Related]
7. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Kuo YC; Kou HW; Hsu CP; Lo CH; Hwang TL
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108495
[TBL] [Abstract][Full Text] [Related]
8. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
[TBL] [Abstract][Full Text] [Related]
9. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells.
Mortoglou M; Miralles F; Arisan ED; Dart A; Jurcevic S; Lange S; Uysal-Onganer P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163198
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer stem cells: features and detection methods.
Ishiwata T; Matsuda Y; Yoshimura H; Sasaki N; Ishiwata S; Ishikawa N; Takubo K; Arai T; Aida J
Pathol Oncol Res; 2018 Oct; 24(4):797-805. PubMed ID: 29948612
[TBL] [Abstract][Full Text] [Related]
11. Fetal bovine serum enlarges the size of human pancreatic cancer spheres accompanied by an increase in the expression of cancer stem cell markers.
Sasaki N; Toyoda M; Hasegawa F; Fujiwara M; Gomi F; Ishiwata T
Biochem Biophys Res Commun; 2019 Jun; 514(1):112-117. PubMed ID: 31027735
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
14. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
[TBL] [Abstract][Full Text] [Related]
15. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
16. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma.
Zhou T; Man Q; Li X; Xie Y; Hou X; Wang H; Yan J; Wei X; Bai W; Liu Z; Liu J; Hao J
Cancer Biol Med; 2023 Mar; 20(3):196-217. PubMed ID: 36971107
[TBL] [Abstract][Full Text] [Related]
17. The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.
Tactacan CM; Phua YW; Liu L; Zhang L; Humphrey ES; Cowley M; Pinese M; Biankin AV; Daly RJ
Mol Cancer; 2015 Jul; 14():139. PubMed ID: 26215634
[TBL] [Abstract][Full Text] [Related]
18. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3.
Karmakar S; Rauth S; Nallasamy P; Perumal N; Nimmakayala RK; Leon F; Gupta R; Barkeer S; Venkata RC; Raman V; Rachagani S; Ponnusamy MP; Batra SK
Gastroenterology; 2020 Nov; 159(5):1898-1915.e6. PubMed ID: 32781084
[TBL] [Abstract][Full Text] [Related]
19. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma.
Jo JH; Kim SA; Lee JH; Park YR; Kim C; Park SB; Jung DE; Lee HS; Chung MJ; Song SY
BMC Cancer; 2021 Nov; 21(1):1241. PubMed ID: 34794402
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
